The role of CD40 in peripheral T cell tolerance and immunity

被引:63
作者
Diehl, L [1 ]
Den Boer, AT [1 ]
van der Voort, EIH [1 ]
Melief, CJM [1 ]
Offringa, R [1 ]
Toes, REM [1 ]
机构
[1] Leiden Univ, Dept Immunohematol & Blood Transfus, Med Ctr, NL-2333 ZA Leiden, Netherlands
来源
JOURNAL OF MOLECULAR MEDICINE-JMM | 2000年 / 78卷 / 07期
关键词
CD40/CD40L; T cell tolerance; T cell immunity; dendritic cell; cytotoxic T lymphocyte; T helper cell;
D O I
10.1007/s001090000126
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
CD40 and CD40 ligand (CD40L) have been implicated as important molecules for the transformation of nonactivated antigen-presenting cells (APC) into cells that are potent inducers of cytotoxic T lymphocyte (CTL) immunity. The onset of a successful immune re -sponse lies within the control of the CD4(+) T helper cells which, after specific antigen recognition, can up-regulate CD40L and subsequently activate APC through CD40 signaling. Triggering of CD40 with antibodies in vivo can replace the need for CD40L-expressing CD4(+) T helper cells for cross-priming of CTL. Blocking of CD40-CD40L interactions can also have profound effects on the generation of T cell immunity. Interesting ly, differential involvement of CD40/CD40L in immune responses can be observed between various immunological sites in the body. In most sites of the periphery interruption of CD40-CD40L interactions can lead to the induction of T cell tolerance whereas in mucosal tissues this interruption can lead to abrogation of T cell tolerance. Furthermore, in vivo CD40 activation can convert specific T cell tolerance following peptide vaccination into efficient T cell priming. Thus intervention of CD40-CD40L interactions can result in enhancement or down-modulation of T cell reactivity and therefore modulation of these interactions may form the foundation of new treatment modalities directed against malignancies, allergies, organ rejections and autoimmunity.
引用
收藏
页码:363 / 371
页数:9
相关论文
共 74 条
[51]   CD40L blockade prevents autoimmune encephalomyelitis and hampers TH1 but not TH2 pathway of T cell differentiation [J].
Samoilova, EB ;
Horton, JL ;
Zhang, HD ;
Chen, YH .
JOURNAL OF MOLECULAR MEDICINE-JMM, 1997, 75 (08) :603-608
[52]   HEPATITIS-B VIRUS SMALL SURFACE-ANTIGEN PARTICLES ARE PROCESSED IN A NOVEL ENDOSOMAL PATHWAY FOR MAJOR HISTOCOMPATIBILITY COMPLEX CLASS I-RESTRICTED EPITOPE PRESENTATION [J].
SCHIRMBECK, R ;
MELBER, K ;
REIMANN, J .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1995, 25 (04) :1063-1070
[53]  
Schoenberger SP, 1998, J IMMUNOL, V161, P3808
[54]   T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions [J].
Schoenberger, SP ;
Toes, REM ;
van der Voort, EIH ;
Offringa, R ;
Melief, CJM .
NATURE, 1998, 393 (6684) :480-483
[55]   PEPTIDE-INDUCED ANTIVIRAL PROTECTION BY CYTOTOXIC T-CELLS [J].
SCHULZ, M ;
ZINKERNAGEL, RM ;
HENGARTNER, H .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (03) :991-993
[56]   A TUMOR ESCAPE VARIANT THAT HAS LOST ONE MAJOR HISTOCOMPATIBILITY COMPLEX CLASS-I RESTRICTION ELEMENT INDUCES SPECIFIC CD8+ T-CELLS TO AN ANTIGEN THAT NO LONGER SERVES AS A TARGET [J].
SEUNG, S ;
URBAN, JL ;
SCHREIBER, H .
JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 178 (03) :933-940
[57]   Cross-presentation of glycoprotein 96-associated antigens on major histocompatibility complex class I molecules requires receptor-mediated endocytosis [J].
Singh-Jasuja, H ;
Toes, REM ;
Spee, P ;
Münz, C ;
Hilf, N ;
Schoenberger, SP ;
Ricciardi-Castagnoli, P ;
Neefjes, J ;
Rammensee, HG ;
Arnold-Schild, D ;
Schild, H .
JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 191 (11) :1965-1974
[58]   Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40 [J].
Sotomayor, EM ;
Borrello, I ;
Tubb, E ;
Rattis, FM ;
Bien, H ;
Lu, ZB ;
Fein, S ;
Schoenberger, S ;
Levitsky, HI .
NATURE MEDICINE, 1999, 5 (07) :780-787
[59]  
SRIVASTAVA PK, 1994, IMMUNOGENETICS, V39, P93
[60]   THE ENDOCYTIC ACTIVITY OF DENDRITIC CELLS [J].
STEINMAN, RM ;
SWANSON, J .
JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 182 (02) :283-288